Campaign
ProVascTec Stage 2
Cell Therapy / BioTech
A UCC spin-out which developed a novel mechanism for the efficient delivery of cell therapies for the treatment of patients suffering from blocked lower-leg arteries.
€
900,000Funding goal
€
30,018Invested
6Investors
Company Summary :
test